{
  "slug": "genomicexpression",
  "name": "Genomicexpression",
  "description": "Genomicexpression analyzes RNA expression to detect disease, monitor health, and design next-generation cures, with an initial focus on oncology. They provide quantitative whole transcriptome analysis for high diagnostic yield, matching patients to approved drugs, and support drug discovery and development for pharmaceutical companies and hospitals with their RNA AI platform.",
  "url": "https://optimly.ai/brand/genomicexpression",
  "websiteUrl": "https://genomicexpression.com/",
  "logoUrl": "https://logo.clearbit.com/genomicexpression.com",
  "baiScore": 57.5,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "Genomic and Multi-Omics Sequencing and Analysis Services",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-09-22T05:44:08.693Z",
  "verifiedVitals": {
    "website": "https://genomicexpression.com",
    "category": "Biotechnology, Diagnostics, Oncology",
    "what_it_does": "Genomicexpression analyzes RNA expression to detect disease, monitor health, and design next-generation cures, primarily in oncology. They aim to provide a high diagnostic yield to match patients with approved drugs and offer an RNA AI platform.",
    "primary_audience": "Clinicians, Pharmaceutical companies, Hospitals, Investors",
    "core_product": "Quantitative whole transcriptome RNA analysis, RNA AI platform",
    "pricing_model": {
      "kind": "transactional",
      "detail": "Clinically validated and RNA-seq-specific payor code, reimbursed."
    },
    "parent_ownership": null
  },
  "intentTags": {
    "problemIntents": [
      "Treatment stops working or recurs",
      "Time and cost curve for drug discovery and development",
      "Detecting disease",
      "Monitoring health",
      "Designing next-generation cures",
      "Limited gene panels for diagnostics"
    ],
    "solutionIntents": [
      "RNA expression analysis",
      "Quantitative whole transcriptome analysis",
      "High diagnostic yield",
      "Matching patients to approved drugs/trials",
      "Target validation for drug discovery",
      "Building companion diagnostics",
      "RNA AI platform",
      "Bending time and cost curve for drug development"
    ],
    "evaluationIntents": [
      "Diagnostic yield comparison",
      "RNA-seq validation",
      "CLIA certification",
      "Reimbursement options for diagnostics",
      "AI platform capabilities",
      "Partnerships for drug discovery",
      "Investment opportunities in RNA AI"
    ]
  },
  "businessProfileClaims": [],
  "timestamp": 1790427931302
}